Home > Resources > Whitepapers > Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

MedTech, Medical

Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19

Spotlight

eHealth Innovation @ UHN

Our team improves quality of life by being the go-to place for developing cool and intuitive self-care and remote monitoring technologies for people with chronic diseases. We attract multidisciplinary talents including engineers, software developers, designers, project managers, and researchers. Leveraging our clinical connections with healthcare organizations globally, we develop technologies from users’ perspective, and evaluate our technologies to collect real data to assess their effectiveness and foster changes to better healthcare delivery.

OTHER WHITEPAPERS

Vaccine and Biologics Development in an Emerging Post Pandemic Landscape

whitePaper | September 20, 2022

It is clear within the global health science industry that analytical biosafety testing and advances in developing scientific technologies will play an important role in drug development’s response to the next pandemic.

Innovative strategies to maintain product integrity in Biologic andBiosimilar clinical studies

whitePaper | August 7, 2022

The number of biologic new molecular entities approved by the FDA has increased over the last five years indicates a growing focus on biosimilar.

Biosimilars in the United States 2023–2027

whitePaper | January 31, 2023

The first biosimilar approved under the abbreviated pathway established by the Biologics Price Competition and Innovation Act launched in the U.S. in 2015.

The A to Z of microarrays evolution of a revolutionary solution

whitePaper | May 27, 2023

The Human Genome Project was a monumental effort over more than a decade to determine the human DNA sequence and analyze genetic variation among individuals. The hope was that, armed with this understanding, phenotypic differences would be explainable by genetic variation, and health benefits could follow.

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Liposomal and Nanoparticle Technology at Pfizer Melbourne

whitePaper | November 22, 2022

Specializing in oncology, anti-infective and complex formulations, Pfizer Melbourne provides end-to-end services from development through to commercial manufacture of sterile dosage forms.